FDA Removes REMS Program for Vandetanib in Medullary Thyroid Cancer After Decade of Safe Use

The FDA has removed the Risk Evaluation and Mitigation Strategies (REMS) program for vandetanib查看药品详情 (Caprelsa查看药品详情), eliminating mandatory safety monitoring requirements for the medullary thyroid cancer (搜索)搜索该疾病 treatment after more than a decade of postmarketing oversight demonstrated its safe use profile.

Vandetanib查看药品详情, an oral tyrosine kinase inhibitor approved in 2011 for patients with medullary thyroid cancer (搜索)搜索该疾病 whose disease has spread or cannot be surgically removed, was originally subject to REMS requirements due to the risk of QT prolongation (搜索)搜索该疾病 and potentially fatal arrhythmias (搜索)搜索该疾病, including Torsades de pointes (搜索)搜索该疾病.

Safety Profile Supports REMS Removal

Following more than ten years of postmarketing surveillance, REMS assessments reported no cases of Torsades de pointes (搜索)搜索该疾病 or unexplained sudden deaths among patients in the United States who were treated with vandetanib查看药品详情. Clinical data similarly revealed no concerning safety signals or consistent patterns of heart rhythm abnormalities.

"Cancer specialists now have adequate knowledge about managing the heart rhythm–related risks of this medication," said Richard Pazdur, MD, director of the FDA Oncology Center of Excellence. "Health care providers have incorporated proper safety monitoring into their standard practice, making the formal requirements unnecessary. The mandatory monitoring program has achieved its goals."

Clinical Efficacy Data

A retrospective review published in February 2021 analyzed clinical records from 76 patients with medullary thyroid cancer (搜索)搜索该疾病 treated with vandetanib查看药品详情, demonstrating that a substantial proportion of those who received first- or second-line therapy achieved sustained clinical benefit.

Among all patients treated with vandetanib查看药品详情, the median progression-free survival was 22.7 months (standard deviation 34.7), with a complete response rate of 3.9%, partial response rate of 36.8%, stable disease rate of 43.4%, and progressive disease rate of 3.9%.

Long-Term Treatment Outcomes

The study identified 21 patients as long-term users, defined as those who received vandetanib查看药品详情 for more than 48 months. Among these patients, the median progression-free survival reached 73.2 months (SD 29.0), with response rates of 14.3% complete response, 71.4% partial response, 14.3% stable disease, and 0% progressive disease.

In contrast, non-long-term users (n=55) achieved a median progression-free survival of 13.4 months (SD 18.4), with response rates of 0% complete response, 23.6% partial response, 54.5% stable disease, and 5.5% progressive disease.

The analysis revealed that younger age at diagnosis and absence of confirmed disease progression prior to initiating vandetanib查看药品详情 treatment were potential predictors of durable response, suggesting patients who begin therapy earlier in the disease course may derive prolonged clinical benefit.

Mechanism of Action

Vandetanib查看药品详情 is an oral tyrosine kinase inhibitor with activity against multiple targets, including the EGFR (搜索)搜索该靶点 family, VEGFR (搜索)搜索该靶点 family, RET (搜索)搜索该靶点, BRK, TIE2, members of the EPH receptor kinase family, and members of the Src kinase family.

Safety Considerations

The long-term safety analysis showed that after 48 months of treatment, renal failure (搜索)搜索该疾病 was reported in two patients, while heart failure (搜索)搜索该疾病, cholecystitis, acute pancreatitis, posterior encephalopathy, and skin cancer were each reported in one patient.

With the removal of the REMS program, vandetanib查看药品详情 will continue to be available under its current prescribing information, but oncologists will no longer be required to obtain special certification or follow additional REMS-specific monitoring requirements beyond routine clinical practice.